Anticonvulsant activities of some arylsemicarbazones displaying potent oral activity in the maximal electroshock screen in rats accompanied by high protection indices.
Various semicarbazones derived from aryl aldehydes, phenylalkyl aldehydes, and phenylalkyl ketones as well as some related compounds were evaluated for anticonvulsant activity. Most of the compounds displayed anticonvulsant activity in the maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ) screens accompanied by neurotoxicity when given to mice by the intraperitoneal route. However quantitative data revealed protection indices (TD50/ED50) of less than 4 in general. Oral administration of the compounds to rats led to excellent potency in the MES screen accompanied by high protection indices while virtually no activity in the scPTZ test was displayed. These observations support the theory that one large hydrophobic group (in this case the aryl ring) and two electron donor atoms (present in the semicarbazono group) are requirements for protection in the MES screen. In general, the semicarbazones had rapid onsets of action, and one of the ways in which these compounds displayed their anticonvulsant activity is likely to be interaction with chloride channels. Empirical and semiempirical conformational calculations indicated that certain molecular fragments and hydrophobicity of these molecules affect bioactivity.
Dimmock
J R
JR
College of Pharmacy, University of Saskatchewan, Saskatoon, Canada.
Sidhu
K K
KK
Thayer
R S
RS
Mack
P
P
Duffy
M J
MJ
Reid
R S
RS
Quail
J W
JW
Pugazhenthi
U
U
Ong
A
A
Bikker
J A
JA
D000284:Administration, Oral; D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects / Q000138:chemical synthesis; D004353:Drug Evaluation, Preclinical; D007274:Injections, Intraperitoneal; D007928:Lethal Dose 50; D051379:Mice; D051381:Rats; D012640:Seizures / Q000139:chemically induced / Q000517:prevention & control*; D012664:Semicarbazones / Q000008:administration & dosage* / Q000009:adverse effects / Q000138:chemical synthesis; D016896:Treatment Outcome
D000927:Anticonvulsants; D012664:Semicarbazones